The significance of partial volume effect on the estimation of hypoxic tumour volume with [18F]FMISO PET/CT-Reference-Cited by-同舟云学术

The significance of partial volume effect on the estimation of hypoxic tumour volume with [18F]FMISO PET/CT

Published:2024-05-09 Issue:1 Volume:11 Page:
ISSN:2197-7364
Container-title:EJNMMI Physics
language:en
Short-container-title:EJNMMI Phys

Author:

Kafkaletos Athanasios^ORCID,Mix Michael,Sachpazidis Ilias,Carles Montserrat,Rühle Alexander,Ruf Juri,Grosu Anca L.,Nicolay Nils H.,Baltas Dimos

Abstract

Abstract Background The purpose of this study was to evaluate how a retrospective correction of the partial volume effect (PVE) in [18F]fluoromisonidazole (FMISO) PET imaging, affects the hypoxia discoverability within a gross tumour volume (GTV). This method is based on recovery coefficients (RC) and is tailored for low-contrast tracers such as FMISO. The first stage was the generation of the scanner’s RC curves, using spheres with diameters from 10 to 37 mm, and the same homogeneous activity concentration, positioned in lower activity concentration background. Six sphere-to-background contrast ratios were used, from 10.0:1, down to 2.0:1, in order to investigate the dependence of RC on both the volume and the contrast ratio. The second stage was to validate the recovery-coefficient correction method in a more complex environment of non-spherical lesions of different volumes and inhomogeneous activity concentration. Finally, we applied the correction method to a clinical dataset derived from a prospective imaging trial (DRKS00003830): forty nine head and neck squamous cell carcinoma (HNSCC) cases who had undergone FMISO PET/CT scanning for the quantification of tumour hypoxia before (W0), 2 weeks (W2) and 5 weeks (W5) after the beginning of radiotherapy. Here, PVE was found to cause an underestimation of the activity in small volumes with high FMISO signal. Results The application of the proposed correction method resulted in a statistically significant increase of both the hypoxic subvolume (171% at W0, 691% at W2 and 4.60 × 103% at W5 with p < 0.001) and the FMISO standardised uptake value (SUV) (27% at W0, 21% at W2 and by 25% at W5 with p < 0.001) within the primary GTV. Conclusions The proposed PVE-correction method resulted in a statistically significant increase of the hypoxic fraction (HF) with p < 0.001 and demonstrated results in better agreement with published HF data for HNSCC. To summarise, the proposed RC-based correction method can be a useful tool for a retrospective compensation against PVE.

Funder

Deutschen Konsortium für Translationale Krebsforschung

Universitätsklinikum Freiburg

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40658-024-00643-1.pdf

Reference41 articles.

1. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8. https://doi.org/10.1200/JCO.2003.01.008.

2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee D-J, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8. https://doi.org/10.1056/NEJMOA031317.

3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(2006):567–78. https://doi.org/10.1056/NEJMOA053422.

4. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial 70. Int J Radiat Oncol. 2015;91(2015):916–24. https://doi.org/10.1016/J.IJROBP.2014.12.034.

5. Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Ruo Redda MG, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Adelstein DJ, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland G, Calais B, Campbell J, Caudell S, Chabaud E, Chamorey D, Chaukar KN, Choi O, Choussy L, Collette JJ, Cruz C, Dani E, Dauzier AA, Forastiere P, Garaud V, Gregoire A, Hackshaw E, Haddad BG, Haffty A, Hansen S, Hayoz JC, Horiot B, Jeremic TG, Karrison JA, Langendijk M, Lapeyre E, Lartigau T, Leong QT, Le PPY, Lee F, Lewin A, Lin A, Lopes S, Mehta J, Moon E, Moyal BV, Occéan P, Olmi R, Orecchia B, O’Sullivan J, Overgaard C, Petit H, Quon G, Sanguineti T, Satar J, Simes C, Simon C, Sire S, Staar C, Stromberger P, Strojan S, Temam D, Thomson A, Timochenko V, Torri V, Tseroni J, Vermorken EE, Vokes J, Waldron KD, Wernecke J, Widder BZ. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281–93. https://doi.org/10.1016/J.RADONC.2021.01.013.